ArticlePublic health in practice (Oxford, England)2026
Retrospective analysis of HIV pre-exposure prophylaxis (PrEP) awards under Executive Order 14168 on gender ideology in the U.S. 2012-2025.
Article in Public health in practice (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the potential impact of Executive Order (EO) 14168, which restricts the use of terms such as "gender," "transgender," and "LGBT," on HIV PrEP-specific research funding, communications, and publications in the United States. Study design: A retrospective analysis of federal grant awards related to HIV pre-exposure prophylaxis (PrEP) was conducted using public data sources. Methods: Award titles and abstracts were obtained from the Tracking Accountability in Government Grants System (TAGGS) for grants containing the terms "PrEP" or "pre-exposure prophylaxis" between 2012 and 2025. Grants were coded for the presence of EO-14168-restricted terminology. Award disbursement characteristics and funding amounts were analyzed, with data subset by presidential budgetary periods for political comparison. Results: Among 388 unique grants, 118 (30.4%) contained terminology that would be excluded under EO-14168. The most frequently represented restricted terms were "transgender" and "gender." Mental health research accounted for the largest share of excluded awards. Both Democratic and Republican states experienced reductions in HIV PrEP-specific funding under these exclusions. The total disbursements affected by restricted terminology amounted to nearly $160 million (USD). Conclusions: If applied retrospectively, EO-14168 would have reduced HIV PrEP-specific research funding by nearly $160 million (USD) from 2012 to 2025, with downstream effects of approximately $400 million (USD) in lost economic activity from the NIH. These restrictions could substantially limit HIV prevention research, particularly in populations disproportionately impacted by HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.